Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a Phase I study testing a new drug called HSK46575 in men with metastatic castration-resistant prostate cancer (mCRPC) — prostate cancer that has spread and is no longer responding to standard hormone therapy. **You may be eligible if...** - You are a man aged 18 or older - You have confirmed prostate adenocarcinoma that has spread (metastatic disease on imaging) - Your testosterone is at castration levels (from medical or surgical treatment) - Your cancer has progressed despite hormone therapy and after at least one newer hormone drug and one taxane-based chemotherapy - Your overall health is good (ECOG 0–1) and expected survival is at least 3 months **You may NOT be eligible if...** - You have received certain cancer therapies within the past 4–6 weeks - You still have significant side effects from prior treatments - You have taken certain medications that interact with HSK46575 within the past 14 days - You have unresolved serious medical conditions Talk to your doctor to see if this trial is right for you.